Reviewed by Dr Dan Reardon, NHS A&E doctor with a specialist interest in metabolic health. Published 23rd April 2026.

Most peptides being sold in the wellness market today have not been through the clinical trials required to prove they produce a meaningful effect in humans. A small number (most notably the GLP-1 class and the next-generation Eli Lilly candidate retatrutide, which delivered up to 16.8% weight loss in its first phase 3 trial) have done that work and represent genuine breakthroughs. The category is real. The retail version of it is mostly a story.

Three Storylines Just Converged in the Peptide Market

In April 2026, three developments collided to push peptides into one of the most heavily watched corners of the health market.

The first was regulatory. On 15 April 2026, the US Food and Drug Administration filed a notice in the Federal Register confirming that its Pharmacy Compounding Advisory Committee would meet on 23-24 July 2026 to review seven specific peptides for inclusion on the Section 503A Bulk Drug Substances List, the regulatory category that determines which substances licensed pharmacies can legally compound for individual patients. A second meeting, scheduled before the end of February 2027, will review five more. The peptides under consideration include BPC-157, TB-500, MOTS-c, KPV, Emideltide, Semax and Selank, most of which have been sold in the grey market for years without formal regulatory approval. (Source:Regulatory Affairs Professionals Society.)

The political backdrop matters. HHS Secretary Robert F. Kennedy Jr. publicly championed expanded peptide access on the Joe Rogan Experience podcast on 27 February 2026, framing the previous restrictions as having driven patients toward unregulated overseas suppliers. The FDA review is, in part, a response to that political pressure. (Source: American Journal of Managed Care.)

The second was financial. Within days of the FDA news, Hims & Hers Health (NYSE: HIMS) stock surged 49% across five trading sessions, including an 11% single-day jump. The company had acquired a California-based peptide manufacturing facility in February 2025, positioning it to capitalise immediately if the regulatory pathway opens. The same week, Hims announced the resolution of a long-running legal dispute with Novo Nordisk, securing a partnership to distribute branded Wegovy through its telehealth platform. (Source:Yahoo Finance.)

The third was infrastructure. Protocole, a clinical-grade peptide platform co-founded by Delphine Le Grand and Cindy Yan, emerged from stealth with a $6m seed round led by Rare Capital. The platform connects members with licensed clinicians, offers personalised peptide protocols at $60 per month with vials priced at around $200 each, and sources its compounds from FDA-registered 503A and 503B pharmacies. Membership is referral-only. (Source: Athletech News.)

Three stories. One direction. The market has decided peptides are the next GLP-1.

The science is yet to pick a side.

What Are Peptides, Exactly?

A peptide is a short chain of amino acids; essentially a small fragment of a protein. Peptides function as signalling molecules in the body, telling cells what to do. Insulin is a peptide. So is GLP-1, the gut hormone behind the global weight-loss drug revolution. Doctors have been prescribing peptides for roughly a century. Insulin was first isolated in 1921.

This last point matters because it directly contradicts the framing that has powered the current investment cycle.

“People talk about peptides like they’re new. That’s where the nonsense begins,” says Dr Dan Reardon, an NHS A&E doctor with a specialist interest in metabolic health.

Reardon’s perspective on the peptide boom isn’t theoretical. He sees its consequences. In an average week he treats multiple patients presenting with complications from unregulated injectable use, such as infections from contaminated compounds, cardiac events from stacked stimulants, hormonal side effects from products bought online. He has treated patients as young as 15 for steroid-related complications. He has spent more than a decade following the performance pharmacology space, including as a former contributor to Muscle and Fitness and Flex magazines.

That combination, clinical exposure to what’s actually being injected, plus deep knowledge of the marketing apparatus selling it, gives him a vantage point most commentators on the peptide boom simply don’t have.

“Insulin is a peptide hormone. GLP-1, which everyone talks about now, was discovered in 1982. We’ve been using peptides in medicine for years. There’s nothing new about them. What’s happened is some peptides partially went through the process of clinical trials and ultimately they failed. But there was a process of discovery, and some of those failed products have ended up in the peptide markets.”

The pitch decks driving the current capital cycle tend to be light on this backstory. Capital, as a rule, prefers novelty.

Why GLP-1 Is the Wrong Comparison for Most Peptides on the Market

The reason GLP-1 drugs like Ozempic, Wegovy and Mounjaro reshaped global metabolic health is not because GLP-1 was a recent discovery. It’s because the molecule went through forty years of pharmaceutical development before it reached the form consumers know today.

GLP-1 was identified in the early 1980s. The first commercial product, exenatide, used in diabetes, reached the market around 2005. The current generation of weight-loss injectables took another two decades on top of that.

Reardon explains the journey:

“Initially they discovered GLP-1 and GLP-2. Eventually they realised that GLP-1 had an effect on appetite, increased the amount of insulin you released, and suppressed glucagon. But from that point to today, it’s been 40 years. And the physiological effects of these GLP-1 agonists or analogues, whatever you want to call them, is unbelievable. It’s absolutely unbelievable in terms of the physiological effect.”

Four decades of trials. Failures. Refinement. Safety work. Regulatory review. That is what it takes for a signalling molecule to become a drug that actually works in humans at scale.

Most of the peptides currently being marketed as wellness products have not done that work. Some failed in clinical trials and ended up on the grey market regardless. Most are being marketed on the basis that they affect a particular biological pathway, which is a very different claim from producing a measurable, useful outcome in a real person.

The Core Problem: Affecting a Pathway Isn’t the Same as Producing a Result

This is the conceptual gap most peptide marketing relies on the consumer not noticing.

A common claim made for several popular peptides is that they increase growth hormone or IGF-1 levels. That claim is, in many cases, technically accurate. The problem is that elevated growth hormone does not, on its own, produce the outcomes consumers are buying these products for.

“You can raise a hormone,” Reardon says, “but that doesn’t mean anything useful happens. A lot of bodybuilders know that an elevated growth hormone doesn’t necessarily do anything. There might be a small number of people that do get some benefits, a reduction in joint pain, increased tendon strength, ligament strength, but it’s quite anecdotal.”

He puts the test more simply still:

“If raising growth hormone was genuinely beneficial, we’d all be injecting growth hormone.”

The same logic applies to peptides marketed for cellular energy, mitochondrial function, telomere length and cognitive performance. The signalling pathway may exist. The molecule may even bind to the right receptor. But whether any of that translates into a measurable improvement in a human being’s day-to-day function is, in most cases, unproven.

The Specific Peptides Being Sold and What the Evidence Actually Shows

MOTS-c

One of the most heavily marketed wellness peptides on the market and one of the seven peptides scheduled for FDA advisory committee review in July 2026. The pitch is that MOTS-c activates AMPK signalling pathways and improves cellular energy expenditure.

“It’s a real peptide,” Reardon confirms. “MOTS-c is something that gets produced as a stress response in the mitochondria. So it exists, no one’s disputing that. But the question is, if you inject it into yourself, does that necessarily mean that you’re going to get this upregulation in the mitochondria? There is absolutely no evidence whatsoever that that’s the case. There is no evidence in humans of the contrary to that.”

His verdict: probably not dangerous if it’s clean and properly manufactured. Almost certainly not doing what it’s being sold to do.

TB-500

Marketed for tissue repair, recovery and healing. TB-500 is a synthetic fragment of a naturally occurring peptide called thymosin beta-4. It is also on the list of peptides under FDA advisory committee review in July 2026.

“There is evidence that thymosin beta-4 can improve ocular tissue repair,” Reardon says. “But that’s pretty much it. There’s no other evidence that it does anything else. And then TB-500 has been sold in these fragmented forms, but there’s no evidence it does anything.”

Growth Hormone Releasing Peptides (CJC-1295, Ipamorelin, Sermorelin)

These peptides do affect growth hormone release. The clinical question is whether the resulting elevation produces any meaningful physiological outcome.

“If we’re just boosting growth hormone but not necessarily getting any measurable outcome in terms of improved muscle strength, improved recovery, reduced joint inflammation, reduced joint pain, improved mobility, flexibility, if you’re not getting any of that, then there’s no benefit to actually taking it in the first place.”

GLP-1 (Semaglutide, Tirzepatide)

The exception that proves the rule. Forty years of development. Phase 3 clinical evidence. Marketing authorisation. Demonstrable, dramatic, repeatable outcomes in real patients.

This is what the rest of the category is being priced against. Almost none of it has earned the comparison.

The One Peptide on the Horizon That Might Genuinely Matter

Reardon is not categorically pessimistic about the future of the category. There is one specific candidate he flags as genuinely significant: retatrutide, a next-generation drug from Eli Lilly that has now produced its first major phase 3 readout.

Retatrutide is a triple agonist, acting on the GIP, GLP-1 and glucagon receptors simultaneously. On 19 March 2026, Eli Lilly announced topline results from its TRANSCEND-T2D-1 phase 3 trial in adults with type 2 diabetes. Participants taking the highest dose achieved an average A1C reduction of up to 2.0% and lost an average of 36.6 lbs (16.8% of body weight) at 40 weeks. Critically, no weight loss plateau was observed — participants were still losing weight at the end of the trial. (Source: Eli Lilly investor announcement.)

An earlier phase 3 readout from the TRIUMPH-4 trial in December 2025, in adults with obesity and knee osteoarthritis, showed weight loss of up to 71.2 lbs alongside meaningful reductions in osteoarthritis pain.

Reardon highlighted what makes retatrutide scientifically distinct before the data dropped:

“I think retatrutide is really interesting. And it’s not necessarily because of the GLP-1 or GIP part, though that’s unbelievable in itself, it’s the glucagon agonist piece. It’s this idea that we can get improvements in cellular energy expenditure.”

The implication is significant. GLP-1 drugs have transformed weight management primarily by suppressing appetite. Retatrutide may be able to do something different: change the relationship between muscle tissue and energy expenditure, helping people who have historically struggled to build a sustainable relationship with exercise actually feel and benefit from physical activity.

“That might enable them to get the benefits from exercise, contract muscles in the right way, utilise and burn fat in the right way, burn carbs in the right way, see improvements in liver health. That might make this something that’s really, really interesting and potentially life-changing for some people.”

But, and this is the point, retatrutide got there the long way. It’s a regulated pharmaceutical that has been through full clinical trials with results published in peer-reviewed journals. It is not being sold by a compounding pharmacy or a wellness clinic. It earned its position in the conversation. (Source: Eli Lilly retatrutide overview.)

Why the Hype Persists Despite the Thin Evidence

If the human evidence base for most wellness peptides is so thin, why is the market so confident?

Reardon’s answer is that peptides have something most consumer health products don’t: a genuinely compelling narrative.

“The thing with peptides is, it’s a great story. And you can make it make sense. You can listen to people, really animated people, who give these great stories about why these things are so fantastic and all the benefits that you can have from them.”

Peptides sound scientific. They sound precise. They sound like the future. The mechanism explanations are plausible-sounding enough to satisfy a curious consumer who hasn’t read the trial data, which is most consumers.

The doctors actively prescribing peptides in the UK, Reardon notes, tend to come from a particular professional background:

“Classically the doctors that have been injecting Botox and fillers into people. Where their barrier to intervention from the perspective of wellness is quite low and not necessarily always well understood in the long term.”

The Safety Question Nobody Is Talking About

Beyond the efficacy question, there is a separate and more concerning issue: what consumers are actually injecting when they buy peptides through unregulated channels.

“Compounding facilities are getting closed around the world left, right and centre,” Reardon says. “We don’t have that same sort of rigour on overall safety. We should know where the product’s coming from, how it’s been manufactured, how it’s been imported — just some of the basic stuff.”

In an unregulated market, the consumer has no reliable way to verify that the vial they’ve purchased contains what it claims to contain, in the dosage stated, free of contaminants. The FDA review is, in part, an attempt to address this. The agency has historically restricted these compounds because of concerns about immunogenicity, toxicity, impurity risk and inadequate human clinical evidence – concerns that have not gone away just because the political winds have shifted.

Until the regulatory process concludes, the safety floor under the consumer peptide market is significantly lower than buyers tend to assume.

What People Are Actually Injecting (And What They Think They’re Injecting)

Here is the part of the peptide boom that almost no one writing about it from the investor side has had to deal with: what arrives in the vial is frequently not what’s printed on the label.

Reardon describes the gap between consumer perception and clinical reality bluntly.

“People assume that because something has a scientific name and comes in a sealed vial, it’s been quality-controlled. In a regulated pharmacy, that’s true. In the grey market, which is where most of these peptides are bought, it’s not.”

The structural problem is that compounding facilities producing peptides for international sale have been closing or being shut down across multiple jurisdictions over the past two years, including in Asia, Eastern Europe and parts of the United States. The supply chain has fragmented. New entrants have moved in. Quality control has not always followed.

In practice, this means a consumer ordering a peptide online may receive:

• A product containing less of the active compound than stated, sometimes substantially less.
• A product containing endotoxins (bacterial contaminants left over from poor manufacturing) which can cause anything from injection-site reactions to systemic infection.
• A product mixed with other compounds entirely, including in some cases active anabolic steroids that the buyer did not know they were purchasing.
• A product that is simply inert, such as saline or filler with no active peptide at all.

There is currently no requirement for grey-market peptide vendors to test or disclose any of this. The buyer has no realistic way to verify what they’ve injected until something goes wrong.

This is the safety floor under most of the consumer peptide market today. It is also the reason that even clinicians who are open to peptide therapy are insistent that the only acceptable route is a regulated pharmacy operating under physician oversight.

“It’s not the molecule I’m worried about with most of these peptides,” Reardon says. “It’s everything that comes with it when there’s no regulation in the supply chain.”

What Happens Next: Three Forces Will Decide This Market

1. The FDA review will reshape who gets to sell what. The 23-24 July 2026 advisory meeting is the start of a multi-step process: committee vote, FDA review, draft rule, public comment period, final rule implementation. Even under the most optimistic scenario, broad legal availability of compounded versions of these peptides is unlikely before late 2026 at the earliest. If the agency tightens restrictions, expect significant disruption to the current direct-to-consumer market. If it creates a clearer commercial pathway, expect rapid consolidation as legitimate operators scale and grey-market sellers exit.

2. Retatrutide’s full phase 3 readout will reset the bar. Eli Lilly has seven additional phase 3 readouts expected through 2026 across obesity, sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. If the rest of the program holds up, the entire peptide category will be re-evaluated through a much more demanding clinical lens. Wellness peptides marketed on weak evidence will struggle to maintain credibility in a market where genuinely transformative drugs are available by prescription.

3. The narrative-versus-evidence gap will eventually close. Either the science catches up to the marketing, or the marketing collapses into the gap. Both have happened before in adjacent categories, such as collagen, NAD+, nootropics and the pattern is consistent. Hype cycles run ahead of evidence until either evidence arrives or the hype runs out of money.

The Five-to-Ten Year View

Peptides as a category will almost certainly produce significant medical breakthroughs over the next decade. The biology is real, the investment is enormous, and the GLP-1 success has demonstrated what the category can do when it’s developed properly.

But the version of peptides currently being sold to consumers –  the wellness vials, the longevity protocols, the recovery shortcuts marketed on Instagram by clinics that also do filler, is unlikely to survive the combination of regulatory tightening, competition from properly developed pharmaceuticals, and the slow erosion of consumer patience with products that under-deliver on dramatic claims.

The science of peptides is genuinely exciting. They may well prove to be the future.

The question is whether the current fervour is about a breakthrough or about the money chasing one.